Literature DB >> 16869842

Persistence of drug use during imprisonment: relationship of drug type, recency of use and severity of dependence to use of heroin, cocaine and amphetamine in prison.

John Strang1, Michael Gossop, Joan Heuston, John Green, Christopher Whiteley, Anthony Maden.   

Abstract

AIM: To investigate the persistence of use of heroin, cocaine and amphetamine drugs during imprisonment, and to identify factors associated with increased levels of persistence.
DESIGN: The use of heroin, cocaine and amphetamine by current prison inmates has been examined and, in particular, the relationship between drug use within prison and the type of drug used prior to imprisonment, recency of use and severity of dependence. SETTING AND PARTICIPANTS: A randomly selected sample of 1009 adult male prisoners in 13 prisons in England and Wales during 1994/95; structured confidential interviews conducted by independent research staff. Enquiry about prior use of heroin, cocaine or amphetamine focused on three time-periods (ever, last year and last month pre-prison) and the use of these drugs during the first month of imprisonment.
FINDINGS: A total of 557 (55%) of the 1009 prisoners had used previously one of the three drugs selected for study: 58% had used heroin, 69% cocaine and 75% amphetamine. More than half (59%; 327/557) had used these drugs in the month before the current imprisonment. Drug use in prisons was most likely to occur among those who had used in the month prior to imprisonment. The persistence of heroin use in prison occurred more frequently (70%) than use of cocaine (20%) or amphetamine (15%). Of those using heroin pre-imprisonment, 67% considered they were dependent, compared to 15% and 22%, respectively, for cocaine and amphetamine users.
CONCLUSIONS: Changes in the drug-taking behaviour of drug users after imprisonment vary according to the type of drug being taken. Prisoners were much more likely to continue to use heroin than either cocaine or amphetamines while in prison. Heroin was most likely to be used by those who had been using heroin during the immediate pre-imprisonment period, and particularly by the two-thirds of heroin users who considered themselves dependent. In view of the high prevalence of prior use of these drugs by individuals currently imprisoned, continuing attention is required to study of their behaviour and of the impact of interventions that may be introduced during or following their incarceration.

Entities:  

Mesh:

Year:  2006        PMID: 16869842     DOI: 10.1111/j.1360-0443.2006.01475.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  14 in total

1.  Individual Patient and Program Factors Related to Prison and Community Treatment Completion in Prison-Initiated Methadone Maintenance Treatment.

Authors:  Timothy W Kinlock; Michael S Gordon; Robert P Schwartz; Kevin E O'Grady
Journal:  J Offender Rehabil       Date:  2013-10

2.  Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.

Authors:  Michael S Gordon; Frank J Vocci; Terrence T Fitzgerald; Kevin E O'Grady; Charles P O'Brien
Journal:  Contemp Clin Trials       Date:  2016-12-20       Impact factor: 2.226

3.  A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release.

Authors:  Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Kevin E O'Grady; Terrence T Fitzgerald; Frank J Vocci
Journal:  Drug Alcohol Depend       Date:  2017-01-11       Impact factor: 4.492

4.  Medication-assisted treatment research with criminal justice populations: challenges of implementation.

Authors:  Michael S Gordon; Timothy W Kinlock; Patrice M Miller
Journal:  Behav Sci Law       Date:  2011 Nov-Dec

5.  Detection of the ethanol consumption markers ethyl glucuronide and ethyl sulfate in urine samples from inmates of two German prisons.

Authors:  Annette Thierauf-Emberger; Anette Franz; Volker Auwärter; Laura M Huppertz
Journal:  Int J Legal Med       Date:  2015-07-10       Impact factor: 2.686

6.  A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry.

Authors:  Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Terrence T Fitzgerald; Kevin E O'Grady; Frank J Vocci
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

7.  Organizational-level correlates of the provision of detoxification services and medication-based treatments for substance abuse in correctional institutions.

Authors:  Carrie B Oser; Hannah K Knudsen; Michele Staton-Tindall; Faye Taxman; Carl Leukefeld
Journal:  Drug Alcohol Depend       Date:  2008-12-23       Impact factor: 4.492

8.  Nonmedical Opioid Use in Relation to Recency of Heroin Use in a Nationally Representative Sample of Adults in the United States.

Authors:  Joseph J Palamar; Jenni A Shearston
Journal:  J Psychoactive Drugs       Date:  2017-09-12

9.  A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release.

Authors:  Timothy W Kinlock; Michael S Gordon; Robert P Schwartz; Kevin O'Grady; Terrence T Fitzgerald; Monique Wilson
Journal:  Drug Alcohol Depend       Date:  2007-07-12       Impact factor: 4.492

10.  Elevated HIV risk behaviour among recently incarcerated injection drug users in a Canadian setting: a longitudinal analysis.

Authors:  M-J S Milloy; Jane Buxton; Evan Wood; Kathy Li; Julio S G Montaner; Thomas Kerr
Journal:  BMC Public Health       Date:  2009-05-27       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.